AbbVie Inc. (NYSE:ABBV)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Credit Suisse Group in a research report issued to clients and investors on Sunday. They presently have a $94.00 price target on the stock, up from their prior price target of $74.00. Credit Suisse Group’s target price points to a potential upside of 5.78% from the stock’s current price.

Several other equities research analysts have also recently issued reports on ABBV. Barclays PLC restated a “hold” rating and set a $68.00 price objective on shares of AbbVie in a research report on Thursday. Evercore ISI reiterated an “outperform” rating and set a $100.00 price target (up from $95.00) on shares of AbbVie in a research report on Saturday. Piper Jaffray Companies reiterated a “buy” rating and set a $85.00 price target on shares of AbbVie in a research report on Thursday, August 3rd. BMO Capital Markets reiterated a “hold” rating and set a $66.00 price target on shares of AbbVie in a research report on Thursday. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $107.00 price target on shares of AbbVie in a research report on Thursday. Ten equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $87.84.

Shares of AbbVie (ABBV) traded down 0.11% during trading on Friday, reaching $88.86. 6,769,367 shares of the company traded hands. The stock has a market capitalization of $141.65 billion, a PE ratio of 16.89 and a beta of 1.48. The firm has a 50 day moving average of $75.76 and a 200 day moving average of $69.87. AbbVie has a 52 week low of $55.06 and a 52 week high of $90.95.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The firm had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. During the same period last year, the business earned $1.26 earnings per share. AbbVie’s revenue was up 7.6% compared to the same quarter last year. On average, equities analysts predict that AbbVie will post $5.52 EPS for the current year.

WARNING: “AbbVie Inc. (ABBV) Stock Rating Reaffirmed by Credit Suisse Group” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/abbvie-inc-abbv-stock-rating-reaffirmed-by-credit-suisse-group/1601640.html.

In other news, insider Henry O. Gosebruch sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $70.09, for a total transaction of $1,261,620.00. Following the completion of the sale, the insider now owns 96,074 shares in the company, valued at approximately $6,733,826.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert A. Michael sold 6,699 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the sale, the vice president now owns 10,007 shares of the company’s stock, valued at approximately $880,616. The disclosure for this sale can be found here. Insiders sold 379,890 shares of company stock valued at $27,187,817 in the last quarter. 0.23% of the stock is owned by insiders.

Large investors have recently modified their holdings of the company. Acropolis Investment Management LLC purchased a new stake in shares of AbbVie during the 2nd quarter worth approximately $106,000. Ffcm LLC lifted its position in shares of AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after buying an additional 963 shares during the last quarter. Hudock Capital Group LLC lifted its position in shares of AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after buying an additional 806 shares during the last quarter. BDO Wealth Advisors LLC purchased a new stake in shares of AbbVie during the 2nd quarter worth approximately $115,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of AbbVie during the 1st quarter worth approximately $108,000. Institutional investors and hedge funds own 68.25% of the company’s stock.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.